この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
規制と法律 · 2023/10/191 分で読めます
Prospective Grant of Exclusive Patent Commercialization License: Human Monoclonal Antibodies That Broadly Target Coronaviruses
ローカル自動翻訳 · 情報源の原言語
概要
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Leyden Laboratories B.V., located at Emmy Noetherweg 2, 2333 BK Leiden, the Netherlands to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice.
情報源の原言語: Federal Register — All Documents原文の発表を開く →